Rhopressa: Phase III started

Aerie began the double-blind, U.S. Phase III Rocket 1 and Rocket 2 trials comparing 0.02% Rhopressa eye drops vs. twice-daily timolol in patients with glaucoma or ocular hypertension. Rocket 1 is evaluating once-daily Rhopressa while Rocket 2 is evaluating once- and twice-daily Rhopressa. The company expects 3-month efficacy results in mid-2015. ...